newsfilter
← Latest News
Business Wire·

Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to Become Publicly Traded via Business Combination with Social Capital Suvretta Holdings Corp. III

ProKidney offers a first-of-its-kind, patented disease-modifying autologous cell therapy for treatment of chronic kidney disease ("CKD") Lead product candidate, REACT®, has potential to slow, stabilize, and even reverse decline in kidney funct